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S U M M A R Y
Background: Namibia experienced a large measles outbreak starting in 2009, with 38% of 
reported cases in adults, including women of reproductive age. Population immunity was assessed 
among pregnant women to determine whether immunization activities were needed in adults to 
achieve measles elimination in Namibia.
Methods: A total of 1708 and 2040 specimens sampled from Namibian pregnant women aged 
15–44 years who were included in the 2008 and 2010 National HIV Sentinel Survey, respectively, 
were tested for measles immunoglobulin G antibody. The proportion of women seropositive 
overall and by 5-year age strata was determined, and factors associated with seropositivity were 
analyzed by logistic regression, including age, facility type, gravidity, HIV status, and urban/rural 
setting. Seropositivity in 2008 versus 2010 was compared.
Results: In both analysis years, measles seropositivity was lower in 15–19-year-olds (77%) and 
20–24-year-olds (85–87%) and higher in 25–44-year-olds (90–94%) (2008, p < 0.001; 2010, p < 
0.001). Overall measles seropositivity did not differ between 2008 (87%) and 2010 (87%) (p = 
0.7). HIV status did not affect seropositivity.
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Conclusions: Late in a large measles outbreak, 13% of pregnant women in Namibia, and almost 
one in four 15–19-year-old pregnant women, remained susceptible to measles. In Namibia, 
immunization campaigns with measles-containing vaccine should be considered for adults.
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1. Introduction
Globally, the number of reported measles cases decreased by 73% from 2000 to 2014.1 In 
the World Health Organization (WHO) African Region, estimated measles deaths decreased 
during this period by 86%; nonetheless, outbreaks continued to occur in this region and 
accounted for 73 914 cases and an estimated 48 000 deaths in 2014, representing 42% of the 
global measles mortality burden.1
In the pre-vaccine era, measles was primarily an illness affecting children, and infection in 
young adults and during pregnancy was uncommon, estimated to occur in 6 per 100 000 
pregnancies.2,3 However, as measles vaccine coverage increased in countries, the chance of 
measles virus exposure in childhood decreased substantially and the age at onset of disease 
shifted to include young adults and women of reproductive age.4–6 During 2009–2010, 
measles outbreaks in a number of African countries demonstrated this shift in measles 
epidemiology, characterized by cases occurring among older children and young adults.4
Namibia, a country in southwestern Africa, has an estimated population of 2.1 million.7 In 
2014, Namibia had an HIV prevalence among adults aged 15–49 years of 16.0%, one of the 
highest in the world,8 and high compared with other countries in the Sub-Saharan Africa 
region.9 Routine measles vaccination at 9 months of age began in 1983, before independence 
from South Africa.10 WHO and United Nations Children’s Fund estimates of coverage 
among 12–23-month-olds with the first dose of measles-containing vaccine in Namibia 
decreased from 76% in 1989 to 58% in 2001, ranged from 63% to 76% during 2002–2012, 
and increased to 83% in 2014.10 In addition to vaccination through routine immunization 
services, periodic measles supplementary immunization activities (SIAs) have been 
conducted every 3 years, starting in 1997, following the WHO-recommended strategy for 
measles mortality reduction, with reported administrative coverage of 90–104%.11,12
From August 2, 2009 through February 2, 2011, a large measles outbreak occurred in 
Namibia, with 3256 laboratory-confirmed or epidemiologically linked cases.11,13 A 
distinguishing feature of this outbreak was that 38% of reported cases occurred among 
adults aged ≥15 years, including women of reproductive age. Measles cases in pregnant 
women in Namibia during this outbreak resulted in adverse maternal, fetal, and neonatal 
outcomes, including neonatal and maternal death.14 In response to the outbreak, outbreak 
response immunization (ORI) targeting children aged 6–59 months, regardless of previous 
measles vaccination, was conducted in seven districts in 2009–2010.13 ORI targeting all 
persons aged ≥6 months was implemented in February 2010 in Opuwo district, where the 
highest number of measles cases was reported during the outbreak,13,15 and ORI targeting 
persons aged 6 months to 35 years was conducted in three districts during May–June 2010.
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To estimate measles population immunity in Namibian pregnant women before and late in 
the measles outbreak and to examine factors associated with seroprevalence (including HIV 
status), stored serum samples from the 2008 and 2010 national HIV surveys among pregnant 
women aged 15–44 years old were tested. It was reasoned that assessing the level of measles 
immunity in pregnant women in Namibia would provide substantial new knowledge towards 
understanding the level of susceptibility and the potential burden of disease in this 
population and would help guide immunization program activities needed in Namibia to 
achieve measles elimination.
2. Methods
2.1. National HIV Sentinel Survey
In 2008 and 2010, the Namibia Ministry of Health and Social Services (MoHSS) conducted 
a nationwide sentinel survey to estimate HIV prevalence in pregnant women aged 15–49 
years. The survey was designed in accordance with the WHO standardized methodology for 
HIV prevalence surveys using convenient consecutive sampling of women attending 
antenatal clinic (ANC) service sites selected based on geographic representation from all 
regions and health districts, urban and rural clinics, areas with different population densities 
and sizes, and women of different socioeconomic status.16,17 All pregnant women aged 15–
49 years were included in the survey if they attended an ANC for the first time during their 
current pregnancy, were not referred from another health facility, and agreed to a routine 
blood draw.
The 2008 survey enrolled 8174 women from all 34 districts, 35 main hospital sites, and 89 
satellite health centers and clinics; 8024 (98.2%) enrollees had specimens collected during 
March 17 to July 31, 2008.17 The 2010 survey enrolled 7983 pregnant women from all 34 
districts, 35 main hospitals, and 93 satellite health centers and clinics; 7888 (98.8%) 
enrollees had specimens collected during March 22 to September 6, 2010.16 Most confirmed 
measles cases in the 2009–2011 outbreak occurred before the start of the 2010 survey (2519 
of the 3256 confirmed cases, or 77%).13 In both surveys, unlinked, de-identified specimens 
were tested for HIV antibodies; all de-identified data fields were retained electronically 
(unique identification, district abbreviation and site number, facility type, date of ANC visit, 
woman’s age, gravidity, town of residence, antiretroviral therapy participation, and 
counseling for prevention of maternal to child transmission). Specimens were stored at 4–
8 °C at the Namibia Institute of Pathology (NIP) in Windhoek.
2.2. Laboratory testing
Laboratory testing to detect measles-specific immunoglobulin G (IgG) antibody was 
performed at the NIP in 2012, using an enzyme immunoassay (EIA) (Enzygnost, Siemens, 
Germany); the manufacturer’s recommended standard operating procedures were followed. 
The manufacturer assigns specimens with corrected optical density (OD) values >0.2 as 
positive, specimens with values of 0.1–0.2 as equivocal, and specimens with values <0.1 as 
negative. However, these classifications are designed for testing individuals and not 
population studies.18 Using the quantitative evaluation recommended by the manufacturer, 
sample assays in the equivocal range resulted in titers ranging from 149 to 342 mIU/ml, 
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which are higher than the accepted protective antibody concentration of 120 mIU/ml.19,20 
As a result, specimens with OD ≥0.1 were considered to be positive, which is consistent 
with previous studies suggesting the antibody levels in the equivocal range are protective 
against measles.18,21,22 Positive, equivocal, and negative specimens are reported separately, 
but analyses were conducted using a combined grouping of positives and equivocals 
compared to negative specimens. Specimens that tested equivocal were retested as per the 
manufacturer’s instructions, and if the result was confirmed, samples were classified as 
equivocal, otherwise as positive or negative.
To monitor the performance of the EIA assay, an in-house positive control for measles IgG 
was included on every EIA plate in addition to the controls supplied by the manufacturer. A 
5% random sample of specimens was tested at the Centers for Disease Control and 
Prevention (CDC) in Atlanta, USA, for quality assurance; testing was found to be highly 
concordant with that at NIP (data not shown).
2.3. Sample size calculations
To estimate measles antibody seroprevalence within each 5-year age group with a desired 
precision of ±5%, it was determined to be necessary to test 428 specimens in each age 
group, assuming a seroprevalence of 50%, probability of achieving the desired precision of 
0.95, and 10% loss due to specimens not found or inadequate for testing. The number of 
specimens in the 45–49 years age stratum was too few to result in meaningful estimates and 
these samples were excluded. The number of specimens in the 40–44 years age stratum was 
fewer than the target, so all specimens were sampled. To control for the distribution of HIV-
infected women within each age group, the target sample size was allocated to the HIV-
positive and HIV-negative groups based on the observed distribution in the ANC sentinel 
survey.16,17
2.4. Statistical analyses
A seroprevalence estimate and 95% confidence interval (CI) using the Wilson score method 
were calculated for each 5-year age group in each analysis year and within the following 
sub-populations: urban/rural setting, HIV status, gravidity, facility type (hospital, health 
center, or clinic), and health district. For each analysis year, multiple logistic regression 
calculated the odds of seropositivity (positives and equivocals vs. negatives) while 
controlling for age group, urban/rural setting, HIV status, gravidity, and facility type. For the 
comparison of measles seroprevalence before and late in the outbreak in 2008 and 2010, the 
analysis was restricted to those birth cohorts present in both 2008 and 2010, and adjusted for 
the age they would have been in 2008, calculating an adjusted odds ratio (OR) for difference 
by year. All analyses included sampling weights, which were calculated based on the 
probability of selection of a specimen within each of the 12 age and HIV status strata from 
all specimens collected, and adjusted for non-response (i.e., specimens unavailable or 
inadequate for testing) in each of the strata by the propensity cell adjustment method. These 
weights were then scaled to the total sample size: (weight/sum of weights) × total sample. A 
large percentage of specimens were unavailable or inadequate for testing. However, 
demographic information was available for all women sampled, so multiple imputation was 
conducted using chained equations to impute seropositivity; the imputed results were 
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compared with estimates based on available data. As the imputed estimates were not 
substantially different from the estimates based on the complete non-missing data, only the 
laboratory results from complete specimens tested are reported. The multiple imputations 
were done using the mice package in R statistical software version 3.1.2. Other data were 
analyzed using SAS version 9.3 (SAS Institute, Cary, NC, USA). Comparisons of 
seroprevalence among groups and between analysis years were calculated using the Mantel–
Haenszel and Chi-square tests on the weighted data. This study received ethical approval 
from the CDC and the Namibia MoHSS.
3. Results
Of the 2638 specimens collected in 2008 that were selected for inclusion in the study, 1708 
(64.7%) were tested (Table 1); 443 (16.8%) were unavailable, 437 (16.6%) had insufficient 
volume, one (0.04%) was hemolyzed and could not be used for laboratory testing, and 49 
(1.9%) were missing the measles IgG laboratory result. Of the 2692 specimens collected in 
2010 that were selected for inclusion in the study, 2040 (75.8%) were tested (Table 2); 389 
(14%) were unavailable, 230 (8%) had insufficient volume, 29 (1%) were hemolyzed and 
could not be used for laboratory testing, and four (0.1%) were missing the measles IgG 
laboratory result. No substantial differences in the demographics of persons whose 
specimens were not tested and those of persons whose specimens were tested and included 
in the analysis was found, by age group, urban/rural setting, or gravidity (data not shown). A 
larger proportion of HIV-positive (74%) than HIV-negative (27%) specimens collected in 
2008 were unavailable for testing; this was likely due to prior use of these specimens in 
antiretroviral resistance studies. Of the specimens collected in 2010 that were available for 
testing, no difference was observed in the proportion of HIV-positive (24%) and HIV-
negative (24%) specimens.
Overall measles seroprevalence (positives and equivocals) was 87% (95% CI 86–89%) in 
2008 and 87% (95% CI 85–88%) in 2010 (Tables 3 and 4). Measles antibody seroprevalence 
increased with increasing age group in both analysis years; in 2008, seroprevalence was 77% 
for 15–19-year-olds and 91–93% for ≥25-year-olds (p < 0.001), and in 2010, seroprevalence 
was 77% for 15–19-year-olds and 94% for 40–44-year-olds (p < 0.001). Seroprevalence 
differed by gravidity in 2008 (p < 0.001) and 2010 (p < 0.001). No significant differences 
were observed in measles seroprevalence by facility type, HIV status, or urban/rural 
residence in 2008 and 2010. When stratified by age group, no significant differences were 
observed in measles seroprevalence by HIV status (Table 5) or by gravidity (data not 
shown). A comparison of measles seroprevalence in 2008 versus 2010 found no significant 
difference between years (OR 1.04, p = 0.711).
Table 6 shows the results from the multivariable models for 2008 and 2010, calculating the 
odds of measles seropositivity while adjusting for age group, HIV status, facility type, 
gravidity, and urban/rural setting. In 2008 and 2010, women 20 years of age and older had 
higher odds of seropositivity compared with women 15–19 years of age (2008, p = 0.002; 
2010, p = 0.010).
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Table 7 shows the results for measles seroprevalence by health district; in 2008, 
seroprevalence ranged from 57% to 98%, and in 2010, seroprevalence ranged from 69% to 
98%.
4. Discussion
This is the first study of measles antibody seroprevalence in Namibia. Because 13% of 
pregnant women and almost one in four 15–19-year-old pregnant women remained measles-
susceptible late in the outbreak in 2010, this study highlights a population of women and 
their offspring at risk of measles and its complications. As these women age and new birth 
cohorts are added to the population, if SIAs do not target these young adults, overall 
population measles susceptibility might increase from current levels. Conducting periodic 
seroprevalence surveys in areas at high risk of outbreaks could be valuable for identifying 
geographic areas and sub-populations with low measles immunity. An indication of results 
from these surveys, along with vaccination coverage data and case-based surveillance data, 
provide evidence for guiding age-specific vaccine introduction strategies as well as 
determining target age groups for SIAs. The findings of this study, together with other data 
sources such as surveillance data, should help guide ORI and SIA planning, including 
expanding target age groups beyond children when indicated, to reach the ≥93–95% 
population immunity needed to prevent measles outbreaks.23 Theoretical disease modeling 
suggests achieving ≤6% to 8% measles susceptibility in all age groups will likely prevent 
measles outbreaks. However, heterogeneity of susceptibility exists, and higher levels of 
measles susceptibility may occur in infants and preschool aged children; in these settings, it 
may be necessary to achieve a relatively lower level of measles susceptibility in age groups 
known to have the highest contact and virus transmission rates, particularly school-aged 
children and young adults.24
The occurrence of large measles outbreaks might have a significant boosting effect on 
overall population immunity because large numbers of measles-susceptible persons acquire 
immunity naturally following infection during the outbreak. However, in the present study, 
measles seroprevalence among adult pregnant women remained unchanged late in the 
measles outbreak (2010) compared with before the outbreak (2008), suggesting the outbreak 
did not affect population immunity substantially.
No effect of HIV status on measles seroprevalence was found. Past studies have shown a 
decreased serological response to measles vaccination among HIV-infected adults, waning 
immunity following vaccination in HIV-positive infants and children, and lower protective 
immunity to measles among infants born to HIV-infected mothers.25–28 Although HIV 
infection is associated with lower vaccine effectiveness29 and an increased risk of measles 
outbreaks,30 the contribution of the HIV pandemic to measles control and elimination in 
Sub-Saharan Africa appears to be minimal.31–33 The present findings mirror those of a 
Kenyan measles seroprevalence study in HIV-positive and negative adults, which also found 
no differences between these two populations.34 It is likely that an association between HIV 
status and measles seroprevalence was not found because the study population received 
measles vaccination as children and acquired HIV as adults, with no loss of protective 
immunity.34 Because of the severe course of measles in patients with advanced HIV 
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infection, the WHO recommends that, in areas with a high incidence of both HIV and 
measles, the first dose of measles-containing vaccine be administered as early as 6 months of 
age, followed by two additional doses of measles vaccine according to the national 
immunization schedule.23 Measles vaccine should also be administered routinely to 
potentially susceptible, asymptomatic HIV-positive children and adults, and considered for 
those with symptomatic HIV infection if not severely immunosuppressed.23
These findings should be considered in light of certain limitations. First, only pregnant 
women aged 15–44 years were examined in this study, and the ANC survey was not a 
random cross-section of the population of pregnant women. Therefore, the results might not 
be generalizable to all pregnant women or to other age groups and populations in Namibia. 
When feasible, prospective, population-based surveys could be considered to increase the 
generalizability of results and allow for the collection of additional information on variables 
of interest, such as immunization status; however, these studies are time- and resource-
intensive, and utilizing specimens already collected and stored might allow for studies that 
would not otherwise be possible. Second, two cohorts of pregnant women who had 
specimens collected in 2008 and 2010 were tested, thus the same women might have been 
included by chance; however, because the specimens were de-identified and unlinked, it 
could not be determined whether this occurred. This limits inferences regarding differences 
in measles seropositivity between the two populations. Third, measles immunity was 
measured before the end of the outbreak; immunity might have been higher if immunity had 
been measured after the outbreak. However, the second survey was conducted after 77% of 
measles cases had occurred in the outbreak, and it is believed that the additional cases that 
occurred during and after the 2010 survey would not have affected these findings 
substantially. Fourth, fewer HIV-positive specimens were available for testing compared 
with HIV-negative samples for the 2008 study year, and this could have biased the results. 
However, this difference in specimens was not seen in 2010, and similar findings were 
observed in both analysis years, making this bias less likely.
The cutoffs for the EIAs used to determine protective levels of antibody have varied 
considerably in measles seroprevalence studies depending on the methodology used, 
although there is a growing movement to standardize testing and report comparable 
outcomes. Persons with antibody titers in the equivocal and sometimes negative qualitative 
ranges, when retested by plaque reduction neutralization (PRN) test, have been found to 
have protective antibodies against measles.18,21 Additionally, persons who are vaccinated 
may have lower titers than those who are infected with wild-type virus.18,21,35 This may 
explain the differences by age group seen in the present study, with the highest percentage of 
equivocals in the youngest age groups (16–21% in 15–19-year-olds), as these youngest 
cohorts would have had the opportunity to receive measles vaccination through the routine 
immunization program which began in 1983. Unfortunately, this cannot be confirmed 
because the participants’ vaccination histories were not available. Nonetheless, as 
seroprevalence studies expand in settings where adults might have been vaccinated or 
exposed to wild-type virus but documentation of vaccination is not readily available, 
defining the appropriate cutoff for protection is critical for guiding programs and 
standardizing reporting across different settings.
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In Namibia, the results from this study together with other data, including from surveillance 
showing a high age-specific incidence of measles in persons up to 39 years of age, is 
evidence of immunity gaps in adults beyond the usual SIA target groups. Additionally, since 
this study was conducted, measles outbreaks have continued in Namibia in 2013–2014, and 
cases continue to occur in older age groups.36 Based on these recurrent outbreaks in adults 
and lower than expected seroprevalence, the MoHSS is considering implementing a 
nationwide SIA with measles–rubella vaccine among persons aged 9 months to 39 years, a 
target population of 1.8 million persons in 2016.37 If high coverage can be achieved and 
sustained in both routine immunization services and SIAs, Namibia will be one step closer 
to achieving the goal of measles elimination.
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Table 6
Logistic regression calculating the odds of measles seropositivity among pregnant women aged 15–44 years 
from the 2008 and 2010 HIV sentinel surveys, Namibiaa
2008 2010
OR 95% CI p-Value OR 95% CI p-Value
Age group, years 0.002 0.010
 15–19 Ref. Ref.
 20–24 1.80 1.23–2.63 0.002 1.38 0.96–1.98 0.079
 25–29 2.77 1.67–4.59 <0.001 2.09 1.31–3.35 0.002
 30–34 2.76 1.43–5.32 0.002 2.92 1.30–4.05 0.004
 35–39 3.02 1.36–6.73 0.007 3.21 1.54–6.70 0.002
 40–44 2.12 0.72–6.28 0.172 3.72 1.22–11.35 0.021
Facilityb 0.456
 Hospital Ref.
 Health center 0.80 0.48–1.32 0.373
 Clinic 0.99 0.65–1.52 0.974
HIV status 0.307 0.286
 Positive Ref. Ref.
 Negative 1.34 0.76–2.36 0.307 1.22 0.85–1.74 0.286
Gravidity 0.063 0.258
 1 Ref.
 2 1.64 1.10–2.46 0.016 1.39 0.96–2.00 0.080
 3 1.11 0.67–1.84 0.680 1.42 0.89–2.27 0.142
 4+ 1.62 0.89–2.94 0.114 1.48 0.88–2.49 0.139
Setting 0.387 0.067
 Rural Ref. Ref.
 Urban 0.88 0.66–1.18 0.387 1.28 0.98–1.68 0.067
OR, odds ratio; CI, confidence interval.
aSeropositive included both seropositive and equivocal.
b
Data for facility type were not available in 2008.
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